Literature DB >> 12387439

Vulvar cancer.

Timothy P Canavan1, Donna Cohen.   

Abstract

Vulvar cancer was reported in 3,200 women in 1998, resulting in 800 deaths. Recent evidence suggests that vulvar cancer comprises two separate diseases. The first type may develop from vulvar intraepithelial neoplasia caused by human papillomavirus infection and is increasing in prevalence among young women. The second type, which more often afflicts older women, may develop from vulvar non-neoplastic epithelial disorders as a result of chronic inflammation (the itch-scratch-lichen sclerosus hypothesis). Although vulvar cancer is relatively uncommon, early detection remains crucial given its significant impact on sexuality. Diagnosis is based on histology; therefore, any suspicious lesions of the vulva must be biopsied. Excisional or punch biopsy can be performed in the physician's office. Clinicians must closely monitor suspicious lesions because delayed biopsy and diagnosis are common. Once diagnosed, vulvar cancer is staged using the TNM classification system. Treatment is surgical resection, with the goal being complete removal of the tumor. There has been a recent trend toward more conservative surgery to decrease psychosexual complications.

Entities:  

Mesh:

Year:  2002        PMID: 12387439

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  18 in total

1.  Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk population.

Authors:  M Paz Cañadas; F Xavier Bosch; M Luisa Junquera; Maijo Ejarque; Rebeca Font; Elena Ordoñez; Silvia de Sanjosé
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

2.  Perineural Invasion Is an Independent Pathologic Indicator of Recurrence in Vulvar Squamous Cell Carcinoma.

Authors:  Emily R Holthoff; Susanne K Jeffus; Ashita Gehlot; Rebecca Stone; Stephen W Erickson; Thomas Kelly; Charles M Quick; Steven R Post
Journal:  Am J Surg Pathol       Date:  2015-08       Impact factor: 6.394

3.  Immunohistochemical expression of p16 and p53 in vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva.

Authors:  Mauricio Cordoni Nogueira; Ernesto de Paula Guedes Neto; Marcos Wengrover Rosa; Eduardo Zettler; Cláudio Galleano Zettler
Journal:  Pathol Oncol Res       Date:  2006-09-23       Impact factor: 3.201

Review 4.  Recent trends in surgical and reconstructive management of vulvar cancer: review of literature.

Authors:  Salvatore Giovanni Vitale; Gaetano Valenti; Antonio Biondi; Diego Rossetti; Luigi Frigerio
Journal:  Updates Surg       Date:  2015-06-13

5.  Squamous cell carcinoma of the vulva in a virgin patient with Turner syndrome.

Authors:  Omer Lutfi Tapisiz; Onur Topcu; Tayfun Gungor; Bulent Ozdal; Levent Sirvan; Ahmet Yesilyurt
Journal:  J Gynecol Oncol       Date:  2011-09-28       Impact factor: 4.401

6.  Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States.

Authors:  A M Stroup; L C Harlan; E L Trimble
Journal:  Gynecol Oncol       Date:  2007-12-21       Impact factor: 5.482

7.  Primary adnexal adenocarcinoma of the vulva: A diagnosis of exclusion based on location, immunohistochemistry, and pattern of spread.

Authors:  Benjamin L Stueben; Jonathan F Lara
Journal:  Gynecol Oncol Case Rep       Date:  2012-11-17

8.  Condyloma-like squamous cell carcinoma of the vulva: report of two midline cases.

Authors:  Shyam B Verma; Uwe Wollina
Journal:  Clin Cosmet Investig Dermatol       Date:  2012-09-10

9.  Investigation of prognostic significance of CD109 expression in women with vulvar squamous cell carcinoma.

Authors:  Pelin Özün Ozbay; Tekin Ekinci; Seyran Yiǧit; Ali Yavuzcan; Selda Uysal; Ferit Soylu; Fulya Cakalagaoglu
Journal:  Onco Targets Ther       Date:  2013-06-07       Impact factor: 4.147

10.  High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients.

Authors:  Gry Irene Magnussen; Ellen Hellesylt; Jahn M Nesland; Claes G Trope; Vivi Ann Flørenes; Ruth Holm
Journal:  BMC Cancer       Date:  2013-06-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.